Etanercept: Therapeutic use in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 58, Issue SUPPL. 1, 1999, Pages

  Garrison, Leslie ^a   McDonnell, Neil D ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; FC RECEPTOR; HYBRID PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOPATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0032731690     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.2008.i65     Document Type: Review

References (30)

1. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984;312:724-9.
2. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34;1125-32.
3. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25.
4. Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Nature 1989;338:225-8.
5. Keffer J, Probert I., Cazlaris H, et al. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis. EMBO J 1991;10:4025.
6. Husby G, Williams RC Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988;1:363-71.
7. Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
8. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990;49:665-7.
9. Hopkins SJ, Humphreys M, Jayson MIV. Cytokines in synovial fluid. 1. The presence of biologically active and immunoreactive IL-1. Clin Exp Immunol 1988;72:422-7.
10. Tucci MA, Baker R, Mohamed A, Tsao AK, Hughes J. Synovial tissues collected from rheumatoid patients undergoing total joint arthroplasty express markers for acute inflammation. Biomed Sci Instrum 1997;34:169-74.
11. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-1 1, leukemia inhibitory factor, and oncostatin M in rheumatoid arthrits. Arthritis Rheum 1997;40:1096-105.
12. Neidel I, Schuize M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor a in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217-21.
13. Saklatvala J. Tumour necrosis factor (x stimulates resorption and inhibits synthesis of proteoglycan in cartilage. [Letter]. Nature 1986;322:547-9.
14. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-18.
15. Dayer J-M, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2producrion by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
16. Lader CS, Flanagan AM, Prostaglandin E2, Interleukin 1a, and tumor necrosis factor-a increase human osteoclast formation and bone resorption in vitro. Endocrinology 1998; 139:3157-64.
17. Nawroth PP, Bank I, Handley D, Cassimeris J, Chess L, Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin I. J Exp Med 1986;163:1363-75.
18. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison, of monoclonal anti TNF-oc antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995,6:225-30.
19. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;ii:244-7.
20. Brockhaus M, Schoenfeld H-J, Schlaeger E-J, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990;87: 3127-31.
21. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992;89:4845-9.
22. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
23. Brennan FM, Gibbons DL, Cope AP, Katsikis P, Maini RN, Feldmann M. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action. Scand J Immunol 1995,42:158-65.
24. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485-9.
25. Barrera P, Boerbooms AMT, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprinc therapy. Arthritis Rheum 1993;36:1070-9.
26. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
27. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
28. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999;130:478-86.
29. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340: 253-9.
30. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic-shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-702.